Zactima-docetaxel combo can prolong lung cancer survival rates GlaxoSmithKline has failed to gain approval from the Food and Drug Administration for an extended release version of its epilepsy drug Lamictal, according to Bloomberg.com. Innovation boosts acne treatment sales Marketing to women drives foot care Soda’s ‘Big Three’ look to non-fizzy innovation Boomers are natural organic care customers Survey: Consumerdriven health plans on the rise Walgreens.com ranked No. 1 REPORTERS Notebook CRN to sponsor research on healthcare professionals' use of dietary supplements First Previous 892 893 894 895 896 Next Last
